Abstract
Melanoma is a relatively common cancer and is often associated with a dire prognosis once diagnosed as metastatic. Immunomodulatory therapy with high-dose bolus interleukin-2 may provide durable responses, albeit in a small subset of those afflicted with metastatic melanoma. High-dose interleukin-2 is well-known to cause substantial toxicities, both acute and delayed. We report on a single case of syndrome of inappropriate antidiuretic hormone secretion in a patient with metastatic melanoma with metastases to the lung and liver which was associated with high-dose bolus interleukin-2 therapy.
Original language | English (US) |
---|---|
Pages (from-to) | e159-e161 |
Journal | American journal of therapeutics |
Volume | 18 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2011 |
Externally published | Yes |
Keywords
- SIADH
- interleukin-2
- melanoma
- syndrome of inappropriate antidiuretic hormone
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)